- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00326118
Study in Toddlers to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC & to Evaluate Persistence up to 5 Years.
Study to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC With Priorix™, Versus MenC-CRM197 Vaccine With Hiberix™ & Priorix™ in Toddlers Primed With Hib But Not MenC & to Evaluate Persistence up to 5 Years After Vaccination.
The purpose of the primary phase of the study is to demonstrate the non-inferiority of a single dose of GSK Biologicals' Haemophilus influenzae type b and meningococcal C (Hib-MenC) conjugate vaccine when given in the second year of life to subjects primed in infancy with a Hib vaccine, but not with a meningococcal serogroup C vaccine, versus commercially available Hib and MenC vaccines.
In the extension phase, at Years 1, 2, 3, 4 & 5, one blood sample is taken at each year to follow the antibody persistence up to 5 years after vaccination. No additional vaccine is administered during the extension phase. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
Descripción general del estudio
Estado
Condiciones
Descripción detallada
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 3
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Australian Capital Territory
-
Garran, Australian Capital Territory, Australia, 2606
- GSK Investigational Site
-
-
New South Wales
-
Randwick, New South Wales, Australia, 2031
- GSK Investigational Site
-
Westmead, New South Wales, Australia, 2145
- GSK Investigational Site
-
-
Queensland
-
Herston, Queensland, Australia, 4029
- GSK Investigational Site
-
-
South Australia
-
North Adelaide, South Australia, Australia, 5006
- GSK Investigational Site
-
-
Victoria
-
Carlton, Victoria, Australia, 3053
- GSK Investigational Site
-
-
Western Australia
-
Perth, Western Australia, Australia
- GSK Investigational Site
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
Primary phase:
- Subjects whom the investigator believes that their parents/guardians can and will comply with the requirements of the protocol.
- A male or female between, and including, 12 and 18 months of age at the time of vaccination.
- Written informed consent obtained from the parent or guardian of the subject.
- Free of obvious health problems as established by medical history and clinical examination before entering into the study.
- Previously completed routine childhood vaccinations to the best of his/her parents'/guardians knowledge.
- Having completed primary vaccination with two doses of Haemophilus influenzae type b outer membrane protein (Hib-OMP) containing vaccine OR three doses of diphtheria, tetanus, acellular pertussis and Haemophilus influenzae type b (DTPa/Hib) containing vaccine at least 6 months before the study start.
Long-term persistence phase:
- Having participated in the vaccination study 106445
Exclusion Criteria:
For the primary vaccination phase:
- Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
- Chronic administration (defined as more than 14 days) or planned administration of immuno-suppressants or other immune-modifying drugs within six months prior to vaccination.
- Planned administration/administration of a vaccine not foreseen by the protocol during the period starting from 30 days before vaccination and ending 30 days after vaccination.
- Administration of a meningococcal vaccine not foreseen by the study protocol during the period starting at birth and ending at first dose.
- Previous administration of a booster dose of Hib vaccine.
- Previous vaccination against measles, mumps, rubella.
- History of H. influenzae type b, meningococcal serogroup C and/or confirmed measles, mumps or rubella diseases.
- Known exposure to measles, mumps or rubella within 30 days prior to the start of the study.
- Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus infection.
- A family history of congenital or hereditary immunodeficiency.
- History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
- Major congenital defects or serious chronic illness.
- History of neurological disorders or more than one episode of febrile convulsion.
- Acute disease at the time of enrolment.
- Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.
Additional exclusion criteria for the long-term persistence phase: to be checked each year.
- Previous administration of a booster dose of Hib, meningococcal serogroup C vaccines.
- History of H. influenzae type b, meningococcal serogroup C diseases.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Comparador activo: Meningitec + Hiberix Group
Subjects received a single dose of Meningitec™ vaccine co-administered with Hiberix™ and Priorix™ vaccines.
The Meningitec vaccine was administered intramuscularly in the left deltoid region, the Hiberix vaccine was administered intramuscularly in the left thigh region and the Priorix vaccine was administered subcutaneously in the right upper arm.
|
One subcutaneous dose at 12-18 months of age
One intramuscular dose at 12-18 months of age.
One intramuscular dose at 12-18 months of age
|
Experimental: Menitorix Group
Subjects received a single dose of Menitorix™ vaccine co-administered with Priorix™ vaccine.
Menitorix vaccine was administered intramuscularly in the left deltoid region and the Priorix vaccine was administered subcutaneously in the right upper arm.
|
One subcutaneous dose at 12-18 months of age
One intramuscular dose at 12-18 months of age
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentration Greater Than or Equal to 0.15 Micrograms Per Milliliter (µg/mL)
Periodo de tiempo: 1 month after vaccination
|
Anti-PRP antibody concentration greater than or equal to 0.15 µg/mL is indicative of short-term protection.
|
1 month after vaccination
|
Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers Greater Than or Equal to 1:8 Titer
Periodo de tiempo: 1 month after vaccination
|
rSBA-MenC titers greater than or equal to 1:8 titer are indicative of seroprotection.
|
1 month after vaccination
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers Above the Cut-off Values
Periodo de tiempo: Prior to, 1 month, 1 year, 2 years, 3 years and 4 years after vaccination
|
rSBA-MenC titers cut-off values assessed were greater than or equal to (≥) 1:8 (indicative of seroprotection) and ≥ 1:128 titers. Functional anti-meningococcal serogroup C activity (SBA-MenC) was determined by a serum bactericidal test using rabbit complement. For SBA testing at a GlaxoSmithKline (GSK) laboratory up to Year 3 after vaccination, titres were expressed as the reciprocal of the dilution resulting in 50% inhibition. For SBA testing at the Public Health England (PHE), formerly known as Health Protection Agency (HPA), at Year 4, titres were expressed as the reciprocal of the last dilution resulting in at least 50% inhibition. |
Prior to, 1 month, 1 year, 2 years, 3 years and 4 years after vaccination
|
Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers Above the Cut-off Values
Periodo de tiempo: 5 years after vaccination
|
rSBA-MenC titers cut-off values assessed were greater than or equal to (≥)1:8 (indicative of seroprotection) and 1:128 titers.
For SBA testing at the PHE at Year 5, titres were expressed as the reciprocal of the last dilution resulting in at least 50% inhibition.
|
5 years after vaccination
|
Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers
Periodo de tiempo: Prior to, 1 month, 1 year, 2 years, 3 years and 4 years after vaccination.
|
Titers are given as Geometric Mean Titers (GMTs).
Functional anti-meningococcal serogroup C activity (SBA-MenC) was determined by a serum bactericidal test using rabbit complement.
For SBA testing at a GlaxoSmithKline (GSK) laboratory up to Year 3 after vaccination, titres were expressed as the reciprocal of the dilution resulting in 50% inhibition.
For SBA testing at the PHE at year 4 after vaccination, titres were expressed as the reciprocal of the last dilution resulting in at least 50% inhibition.
|
Prior to, 1 month, 1 year, 2 years, 3 years and 4 years after vaccination.
|
Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers
Periodo de tiempo: 5 years after vaccination
|
Titers are given as Geometric Mean Titers (GMTs).
Functional anti-meningococcal serogroup C activity (SBA-MenC) was determined by a serum bactericidal test using rabbit complement.
For SBA testing at the PHE at Year 5, titres were expressed as the reciprocal of the last dilution resulting in at least 50% inhibition.
|
5 years after vaccination
|
Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentration Above Cut-off Values
Periodo de tiempo: Prior to, 1 month, 1 year, 2 years, 3 years and 4 years after vaccination
|
Anti-PRP antibody concentration cut-off values assessed include 0.15 µg/mL (indicative of short-term protection) and 1.0 µg/mL (indicative of long-term protection).
|
Prior to, 1 month, 1 year, 2 years, 3 years and 4 years after vaccination
|
Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentration Above Cut-off Values
Periodo de tiempo: 5 years after vaccination
|
Anti-PRP antibody concentration cut-off values assessed include 0.15 µg/mL (indicative of short-term protection) and 1.0 µg/mL (indicative of long-term protection).
|
5 years after vaccination
|
Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations
Periodo de tiempo: Prior to, 1 month , 1 year, 2 years, 3 years and 4 years after vaccination
|
Concentrations are given as Geometric Mean Concentrations (GMCs).
|
Prior to, 1 month , 1 year, 2 years, 3 years and 4 years after vaccination
|
Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations
Periodo de tiempo: 5 years after vaccination
|
Concentrations are given as Geometric Mean Concentrations (GMCs).
|
5 years after vaccination
|
Number of Subjects With Anti-polysaccharide C (Anti-PSC) Antibody Concentration Above the Cut-off Values
Periodo de tiempo: Prior to, 1 month, 1 year, 2 years and 3 years after vaccination
|
Anti-PSC antibody concentration cut-off values assessed include greater than or equal to (≥) 0.30 µg/mL and ≥ 2.0 µg/mL.
|
Prior to, 1 month, 1 year, 2 years and 3 years after vaccination
|
Anti-polysaccharide C (Anti-PSC) Antibody Concentrations
Periodo de tiempo: Prior to, 1 month, 1 year, 2 years and 3 years after vaccination
|
Concentrations given as Geometric Mean Concentrations (GMCs).
|
Prior to, 1 month, 1 year, 2 years and 3 years after vaccination
|
Number of Subjects Reporting Solicited Local and General Symptoms
Periodo de tiempo: Within 4 days (Day 0 -Day 3) after vaccination
|
Solicited local symptoms assessed include pain, redness and swelling at the injection site. Solicited general symptoms assessed include drowsiness, fever (≥ 38°C), irritability and loss of appetite. |
Within 4 days (Day 0 -Day 3) after vaccination
|
Number of Subjects Reporting Unsolicited Symptoms
Periodo de tiempo: Within 31 days (Day 0 - Day 30) after vaccination
|
Unsolicited symptom: Any adverse event (AE) reported in addition to those solicited during the clinical study.
Also any solicited symptom with onset outside the specified period of follow-up for solicited symptoms will be reported as an unsolicited adverse event.
|
Within 31 days (Day 0 - Day 30) after vaccination
|
Number of Subjects Reporting Serious Adverse Events (SAEs)
Periodo de tiempo: Throughout the entire study period (up to year 5)
|
A serious adverse event (SAE) is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect in the offspring of a study subject. For the long-term persistence phase (Years 1 through 5), only those SAEs that are determined by the investigator to have a causal relationship to the vaccination will be described individually. |
Throughout the entire study period (up to year 5)
|
Colaboradores e Investigadores
Patrocinador
Publicaciones y enlaces útiles
Publicaciones Generales
- Booy R, Richmond P, Nolan T, McVernon J, Marshall H, Nissen M, Reynolds G, Ziegler JB, Heron L, Lambert S, Caubet M, Mesaros N, Boutriau D. Immediate and longer term immunogenicity of a single dose of the combined haemophilus influenzae type B-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in primed toddlers 12 to 18 months of age. Pediatr Infect Dis J. 2011 Apr;30(4):340-2. doi: 10.1097/INF.0b013e31820013d2.
- Booy R, Richmond P, Nolan T, McVernon J, Marshall H, Nissen M, Reynolds G, Ziegler JB, Stoney T, Heron L, Lambert S, Mesaros N, Peddiraju K, Miller JM. Three-year antibody persistence and safety after a single dose of combined haemophilus influenzae type b (Hib)-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in Hib-primed toddlers. Pediatr Infect Dis J. 2013 Feb;32(2):169-74. doi: 10.1097/INF.0b013e3182787bff.
- Booy R et al. Immunogenicity and safety of the Hib-MenC-TT conjugate vaccine in Hib-primed toddlers: 3 year follow-up. Abstract presented at the 7th World Congress for World Society for Pediatric Infectious Diseases (WSPID). Melbourne, Australia, 16-19 November 2011.
- Booy R et al. Immunogenicity and safety of the Hib-MenC-TT conjugate vaccine in Hib-primed toddlers: 4 year follow-up. Abstract presented at the Communicable Diseases Network Australia - Communicable Diseases Control Conference 2013, Canberra, Australia, 19-20 March 2013.
- Booy R et al. Prolonged immunogenicity and safety of the HibMenC-TT conjugate vaccine in Hib-Primed toddlers. Abstract presented at the PHAA Communicable Disease Conference. Canberra, Australia, 4-6 April 2011.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Otros números de identificación del estudio
- 106445
- 106446 (Otro identificador: GSK)
- 106449 (Otro identificador: GSK)
- 106450 (Otro identificador: GSK)
- 106452 (Otro identificador: GSK)
- 106454 (Otro identificador: GSK)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Datos del estudio/Documentos
-
Plan de Análisis Estadístico
Identificador de información: 106445Comentarios de información: For additional information about this study please refer to the GSK Clinical Study Register
-
Formulario de consentimiento informado
Identificador de información: 106445Comentarios de información: For additional information about this study please refer to the GSK Clinical Study Register
-
Protocolo de estudio
Identificador de información: 106445Comentarios de información: For additional information about this study please refer to the GSK Clinical Study Register
-
Especificación del conjunto de datos
Identificador de información: 106445Comentarios de información: For additional information about this study please refer to the GSK Clinical Study Register
-
Conjunto de datos de participantes individuales
Identificador de información: 106445Comentarios de información: For additional information about this study please refer to the GSK Clinical Study Register
-
Informe de estudio clínico
Identificador de información: 106445Comentarios de información: For additional information about this study please refer to the GSK Clinical Study Register
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Neisseria meningitidis
-
University Hospital, RouenInstitut Pasteur; Direction Générale de la Santé, FranceTerminado
-
Public Health EnglandTerminado
-
Public Health EnglandTerminadoNeisseria meningitidis serogrupo BReino Unido
-
Novartis VaccinesTerminado
-
University of AdelaideTerminadoNeisseria meningitidisAustralia
-
Sanofi Pasteur, a Sanofi CompanyTerminadoEnfermedades virales | Infecciones bacterianas | Neisseria meningitidisFinlandia
-
PfizerTerminadoMeningitis | Vacuna meningocócica | rLP2086 | Repevax | N Meningitidis serogrupo BAlemania, Finlandia, Polonia
-
MCM Vaccines B.V.Merck Sharp & Dohme LLC; Sanofi Pasteur, a Sanofi CompanyTerminadoEnfermedades virales | Infecciones bacterianas | Neisseria meningitidis
-
GlaxoSmithKlineTerminadoNeisseria meningitidis | Haemophilus influenzae tipo bEstados Unidos
Ensayos clínicos sobre Priorix™
-
GlaxoSmithKlineTerminadoVaricela | Vacunas contra la varicelaFederación Rusa, Rumania, Chequia, Eslovaquia, Italia, Suecia, Polonia, Grecia, Noruega, Lituania
-
GlaxoSmithKlineTerminadoSarampión | Rubéola | Paperas | VaricelaCorea, república de
-
GlaxoSmithKlineTerminadoSarampión | Rubéola | Paperas | VaricelaIndia
-
GlaxoSmithKlineRetiradoSarampión | Rubéola | Paperas | Varicela
-
GlaxoSmithKlineTerminadoSarampión | Rubéola | Paperas | VaricelaEstados Unidos
-
University of OxfordTerminadoRespuesta inmune | Infección por BCG | Reacción - VacunaReino Unido
-
CHU de Quebec-Universite LavalGlaxoSmithKlineDesconocido
-
Assistance Publique - Hôpitaux de ParisService de Bactériologie-Virologie-Hygiène, CHU Limoge; GO-CIC network (Réseau... y otros colaboradoresTerminado
-
GlaxoSmithKlineTerminado
-
GlaxoSmithKlineTerminadoSarampión | Rubéola | Paperas | VaricelaAlemania, Austria